Broad rim lesions identified as MS disease progression marker
Wider rims of immune cells surrounding multiple sclerosis (MS) lesions in the brain and spinal cord are associated with…
Articles by Marisa Wexler, MS
New AI tool accurately detects transition from RRMS to SPMS
A new machine learning tool, a form of artificial intelligence (AI), may accurately detect the transition from relapsing-remitting multiple…
Biomarkers, aging among topics in new MS care guidelines
New diagnostic criteria and biomarkers, how to manage MS in older patients and children, and vaccine recommendations are among topics…
Disease activity test helps with MS care decisions: Study
Assessing multiple sclerosis (MS) disease activity using Octave Bioscience’s MS Disease Activity (MSDA) blood biomarker test can help guide…
In MS, best exercises for balance may depend on specific issues
Some exercises are better than others at easing certain problems associated with balance in people with multiple sclerosis (MS),…
MS patients in rural regions less likely to receive DMTs, study finds
People with multiple sclerosis (MS) who live in rural areas are 17% less likely to receive disease-modifying therapies…
Tolebrutinib for nonrelapsing SPMS delays disability progression in trial
Sanofi‘s oral BTK inhibitor tolebrutinib significantly delayed the onset of six-month confirmed disability progression compared with a placebo,…
AI tool effectively measures MS disease activity from 1 MRI scan
A new artificial intelligence (AI) tool called MindGlide can accurately calculate, from a single MRI scan, multiple aspects of brain…
Patient support for Bafiertam now offered by Cycle Pharmaceuticals
The patient support program Cycle Vita, which assists patients throughout the process of medical prescriptions, is now available for…
Targeting TYK2 in brain seen as potential strategy for MS treatment
A small molecule that blocks the activity of a protein called TYK2 in the brain showed promise at reducing disease…
FDA grants priority review to application for tolebrutinib for MS
Note: This story was updated April 4, 2025, to clarify the specific disability measures and that tolebrutinib is believed…
Tysabri may reduce risk of disability progression in SPMS: Analysis
Treatment with Tysabri (natalizumab) may help delay disability progression in people with secondary progressive multiple sclerosis (SPMS) over…
AI may help with MS diagnosis, treatment decisions, study finds
Artificial intelligence (AI) platforms did better than most neurologists at answering a 20-question assessment about multiple sclerosis (MS) in…
Antibodies against EBV and genetic factors raise MS risk: Study
Antibodies that target proteins from the Epstein-Barr virus (EBV) also can inadvertently attack proteins in the brain, which may…
Epstein-Barr virus may drive MS by dysregulating certain immune cells
In the lymph nodes of the neck of people with multiple sclerosis (MS), certain immune cells show abnormalities in…
Slowly expanding MS lesions linked to myelin damage in brain
In people with multiple sclerosis (MS), lesions that get slowly bigger over time, potentially due to chronic inflammation, are…
New model could assist in guiding RRMS treatment decisions
A statistical model that takes clinical and demographic factors into account could help guide treatment decisions in people with…
Antibodies against MLC1 protein may drive MS: Study
Antibodies against a protein found in neurons and in nerve supporting cells, may play a role in driving multiple…
Immune system-gut bacteria interactions altered in MS: Study
Interactions between the body’s immune system and bacteria that live in the digestive tract — essentially, a person’s gut —…
Implantable scaffold aids insights into PPMS, treatment strategies
Using an implantable scaffold to collect immune cells in mice, researchers have gained insights into the immunological mechanisms driving…
Living with RRMS: The ‘space between hope and grief’
Navigating the uncertainty of living with relapsing-remitting multiple sclerosis (RRMS) brings a number of challenges, a study shows. That…
MS children exposed to sunlight as babies see less relapse risk
Children with multiple sclerosis (MS) who were exposed to sunlight for at least half an hour per day during…
Australia, New Zealand get consensus guidelines for MS care
Experts in Australia and New Zealand have published the first consensus guidelines for the care of adults with multiple…
Pediatric-onset MS relapse rates rise with start of menstruation
The rate of relapses in children with pediatric-onset multiple sclerosis (POMS) tends to increase around the time that menstruation…
Smoking, obesity interact to drive faster MS progression, study finds
Smoking and obesity are both independently associated with faster disease progression in multiple sclerosis (MS), but when both risk…
Phase 2 trial of obexelimab recruiting adults with relapsing MS
A Phase 2 clinical trial is currently recruiting adults with relapsing types of multiple sclerosis (MS) to investigate…
Less frequent Ocrevus infusions in MS may limit risk of side effects
Less frequent Ocrevus (ocrelizumab) infusions are as effective as standard dosing — when treatment is given typically every six…
ECTRIMS, EBMT suggest stem cell transplant for some with RRMS
Stem cell transplant can be considered a viable treatment option for people with relapsing-remitting multiple sclerosis (MS) who are…
MS drug glatiramer acetate given warning over allergic reaction risk
The U.S. Food and Drug Administration (FDA) has added a new boxed warning to the prescribing information for glatiramer acetate,…
TG developing under-the-skin version of MS therapy Briumvi
TG Therapeutics is working to develop a subcutaneous, or under-the-skin, version of Briumvi (ublituximab-xiiy), its approved therapy…